After bouncing back last year both in dollars raised and number of deals, the initial public offering (IPO) market was expected to at least approach that success this year.
Instead, the 2019 market for first-time public issues of biopharma stock has had its ups, and mostly downs. For U.S. and Western exchanges, a relatively quiet first quarter has been followed by a busier second quarter, according to Evaluate: Q1 saw 13 IPOs totaling $1.04 billion, followed by 20 IPOs totaling $1.952 in Q2.
